(Q36653658)

15 August 2017

1 reference

title

Non-low-density lipoprotein cholesterol-associated actions of ezetimibe: an overview (English)

1 reference

15 August 2017

0 references

1 reference

Dimitri P Mikhailidis

series ordinal

2

object named as

Dimitri P Mikhailidis

1 reference

15 August 2017

Irene F Gazi

1

1 reference

15 August 2017

language of work or name

English

0 references

publication date

1 December 2006

1 reference

Expert Opinion on Therapeutic Targets

15 August 2017

published in

1 reference

15 August 2017

volume

10

1 reference

15 August 2017

issue

6

1 reference

15 August 2017

page(s)

851-866

1 reference

The use of ezetimibe in achieving low density lipoprotein lowering goals in clinical practice: position statement of a United Kingdom consensus panel

15 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Cholesterol absorption blockade with ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Niemann-Pick C1 Like 1 protein is critical for intestinal cholesterol absorption

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Niemann-Pick C1 Like 1 (NPC1L1) is the intestinal phytosterol and cholesterol transporter and a key modulator of whole-body cholesterol homeostasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

The target of ezetimibe is Niemann-Pick C1-Like 1 (NPC1L1)

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

RETRACTED: Annexin 2-caveolin 1 complex is a target of ezetimibe and regulates intestinal cholesterol transport

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Aminopeptidase N (CD13) is a molecular target of the cholesterol absorption inhibitor ezetimibe in the enterocyte brush border membrane

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Comparative effects of lipid-lowering therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Projected coronary heart disease risk benefit with ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Ezetimibe, a potent cholesterol absorption inhibitor, inhibits the development of atherosclerosis in ApoE knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Reaching goal in hypercholesterolaemia: dual inhibition of cholesterol synthesis and absorption with simvastatin plus ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Role of fibrates in reducing coronary risk: a UK Consensus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

High-density lipoprotein and cardiovascular risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Beyond LDL-C--the importance of raising HDL-C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Tangier disease four decades of research: a reflection of the importance of HDL.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Efficacy and safety of a potent new selective cholesterol absorption inhibitor, ezetimibe, in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Inhibition of intestinal cholesterol absorption by ezetimibe in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Ezetimibe effectively reduces plasma plant sterols in patients with sitosterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effectiveness and tolerability of ezetimibe in patients with primary hypercholesterolemia: pooled analysis of two phase II studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effectiveness of ezetimibe in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effects of ezetimibe, a new cholesterol absorption inhibitor, on plasma lipids in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Lipoprotein (a) and stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Serum lipoprotein(a) levels and apolipoprotein(a) isoform size and risk for first-ever acute ischaemic nonembolic stroke in elderly individuals.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Apolipoprotein B and apolipoprotein A-I: risk indicators of coronary heart disease and targets for lipid-modifying therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Lipoprotein-associated phospholipase A2 activity is a marker of small, dense LDL particles in human plasma

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

The effects of ezetimibe on the LDL-cholesterol particle number

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Consistency in efficacy and safety of ezetimibe coadministered with statins for treatment of hypercholesterolemia in women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Efficacy and safety of ezetimibe co-administered with simvastatin compared with atorvastatin in adults with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP III goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-cont

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

A multicenter, randomized, double-blind, placebo-controlled, factorial design study to evaluate the lipid-altering efficacy and safety profile of the ezetimibe/simvastatin tablet compared with ezetimibe and simvastatin monotherapy in patients with p

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Long-term safety and, tolerability profiles and lipid-modifying efficacy of ezetimibe coadministered with ongoing simvastatin treatment: a multicenter, randomized, double-blind, placebo-controlled, 48-week extension study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effect of co-administering ezetimibe with on-going simvastatin treatment on LDL-C goal attainment in hypercholesterolemic patients with coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

LDL-C goal attainment with the addition of ezetimibe to ongoing simvastatin treatment in coronary heart disease patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Lipid altering-efficacy of ezetimibe co-administered with simvastatin compared with rosuvastatin: a meta-analysis of pooled data from 14 clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Efficacy and safety of ezetimibe co-administered with ongoing atorvastatin therapy in achieving low-density lipoprotein goal in patients with hypercholesterolemia and coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Achieving lipoprotein goals in patients at high risk with severe hypercholesterolemia: efficacy and safety of ezetimibe co-administered with atorvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Long-term safety and tolerability profile of ezetimibe and atorvastatin coadministration therapy in patients with primary hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Lipid-altering efficacy of switching from atorvastatin 10 mg/day to ezetimibe/simvastatin 10/20 mg/day compared to doubling the dose of atorvastatin in hypercholesterolaemic patients with atherosclerosis or coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Pharmacodynamic interaction between ezetimibe and rosuvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effects of ezetimibe on the pharmacodynamics and pharmacokinetics of lovastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effectiveness and tolerability of ezetimibe add-on therapy to a bile acid resin-based regimen for hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Colesevelam HCl and ezetimibe combination therapy provides effective lipid-lowering in difficult-to-treat patients with hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Inhibition of cholesterol absorption by the combination of dietary plant sterols and ezetimibe: effects on plasma lipid levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Serum plant sterols as a potential risk factor for coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Markers of inflammation and cardiovascular disease: application to clinical and public health practice: A statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effect of ciprofibrate on C-reactive protein and fibrinogen levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effects of fibrates on serum metabolic parameters.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Fibrates and C-reactive protein.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Targeting vascular risk in patients with metabolic syndrome but without diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Drug-induced acute autoimmune hepatitis during combination therapy with atorvastatin and ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Severe hepatic side effects of ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Statins and renal function in patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effect of atorvastatin on serum uric acid levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effect of statins versus untreated dyslipidemia on serum uric acid levels in patients with coronary heart disease: a subgroup analysis of the GREek Atorvastatin and Coronary-heart-disease Evaluation (GREACE) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Statins and renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Short-term lipid-lowering treatment with atorvastatin improves renal function but not renal blood flow indices in patients with peripheral arterial disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Fibrate treatment can increase serum creatinine levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Fibrate-induced increase in serum urea and creatinine levels.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

The second United Kingdom Heart and Renal Protection (UK-HARP-II) Study: a randomized controlled study of the biochemical safety and efficacy of adding ezetimibe to simvastatin as initial therapy among patients with CKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Monotherapy with ezetimibe causing myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Worsening myopathy associated with ezetimibe in a patient with McArdle disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Ezetimibe and statin-associated myopathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Striated muscle safety of ezetimibe/simvastatin (Vytorin).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effect of ezetimibe and/or simvastatin on coenzyme Q10 levels in plasma: a randomised trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Early vascular benefits of statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Endothelial function in the forearm circulation of patients with the metabolic syndrome--effect of different lipid-lowering regimens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Inactivation of NPC1L1 causes multiple lipid transport defects and protects against diet-induced hypercholesterolemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Ezetimibe, a potent cholesterol absorption inhibitor, normalizes combined dyslipidemia in obese hyperinsulinemic hamsters

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Ezetimibe selectively inhibits intestinal cholesterol absorption in rodents in the presence and absence of exocrine pancreatic function

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Ezetimibe potently inhibits cholesterol absorption but does not affect acute hepatic or intestinal cholesterol synthesis in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Pharmacokinetic interaction between ezetimibe and lovastatin in healthy volunteers

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Interaction of single-dose ezetimibe and steady-state cyclosporine in renal transplant patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Supratherapeutic response to ezetimibe administered with cyclosporine.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effects of ezetimibe on cyclosporine pharmacokinetics in healthy subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Comment: supratherapeutic response to ezetimibe administered with cyclosporine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Phenotypic heterogeneity of sitosterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Plasma sitosterol elevations are associated with an increased incidence of coronary events in men: results of a nested case-control analysis of the Prospective Cardiovascular Münster (PROCAM) study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Plant sterols in serum and in atherosclerotic plaques of patients undergoing carotid endarterectomy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Sterol transporters: targets of natural sterols and new lipid lowering drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Cholesterol and plant sterol absorption: recent insights

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Intestinal cholesterol absorption inhibitor ezetimibe added to cholestyramine for sitosterolemia and xanthomatosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Efficacy and safety of ezetimibe coadministered with atorvastatin or simvastatin in patients with homozygous familial hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

The effect of ezetimibe on serum lipids and lipoproteins in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effects of ezetimibe on plasma lipoproteins in severely hypercholesterolemic patients treated with regular LDL-apheresis and statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Efficacy of ezetimibe in patients with statin-resistant and statin-intolerant familial hyperlipidaemias

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Prevalence of atherosclerotic vascular disease among subjects with the metabolic syndrome with or without diabetes mellitus: the METS-GREECE Multicentre Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Diagnosis and management of the metabolic syndrome in obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Preventing type 2 diabetes in high risk patients: an overview of lifestyle and pharmacological measures.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Effects of ezetimibe added to on-going statin therapy on the lipid profile of hypercholesterolemic patients with diabetes mellitus or metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Efficacy and safety of ezetimibe co-administered with simvastatin in thiazolidinedione-treated type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Ezetimibe in renal transplant patients with hyperlipidemia resistant to HMG-CoA reductase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Ezetimibe for the treatment of uncontrolled hypercholesterolemia in patients with high-dose statin therapy after renal transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

A retrospective analysis of ezetimibe treatment in renal transplant recipients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Synthesis and absorption markers of cholesterol in serum and lipoproteins during a large dose of statin treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Initial low-density lipoprotein response to statin therapy predicts subsequent low-density lipoprotein response to the addition of ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Type of preexisting lipid therapy predicts LDL-C response to ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

NPC1L1 haplotype is associated with inter-individual variation in plasma low-density lipoprotein response to ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Sequence variation in NPC1L1 and association with improved LDL-cholesterol lowering in response to ezetimibe treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Compound heterozygosity for two non-synonymous polymorphisms in NPC1L1 in a non-responder to ezetimibe

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Genetic regulation of cholesterol absorption and plasma plant sterol levels: commonalities and differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Cholesterol absorption: influence of body weight and the role of plant sterols

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

Differential effects of short-term lipid lowering with ezetimibe and statins on endothelial function in patients with CAD: clinical evidence for ‘pleiotropic’ functions of statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14728222.10.6.851

10.1517/14728222.10.6.851

21 January 2018

Identifiers

DOI

1 reference

15 August 2017

1 reference